TY - JOUR
T1 - Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults
AU - Weller, Michael
AU - Le Rhun, Emilie
AU - Van Den Bent, Martin
AU - Chang, Susan M.
AU - Cloughesy, Timothy F.
AU - Goldbrunner, Roland
AU - Hong, Yong Kil
AU - Jalali, Rakesh
AU - Jenkinson, Michael D.
AU - Minniti, Giuseppe
AU - Nagane, Motoo
AU - Razis, Evangelia
AU - Roth, Patrick
AU - Rudà, Roberta
AU - Tabatabai, Ghazaleh
AU - Wen, Patrick Y.
AU - Short, Susan C.
AU - Preusser, Matthias
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here, the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose, and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy, and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions, and reexposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.
AB - Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here, the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose, and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy, and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions, and reexposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85164273583&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noad038
DO - 10.1093/neuonc/noad038
M3 - Article
C2 - 36843451
AN - SCOPUS:85164273583
SN - 1522-8517
VL - 25
SP - 1200
EP - 1224
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 7
ER -
